NervGen Pharma Corp. (NGEN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.35 (-1.46% 1D, market cap $147.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, NGEN ranks #369 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DERM (Journey Medical Corporation) holds a E grade (16/100 RQD, P/E N/A, ROIC -19.5%, cap $145.9M) and PDSB (PDS Biotechnology Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $151.2M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #369 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.1M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While NGEN currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.87) and Max Pain ($1.42) forces dealer call-delta covering toward $6.62.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NervGen Pharma Corp. (NGEN) slipped -1.46% to $1.35, trading at 2% of its 52-week range ($1.35 – $6.3). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Stock Titan report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
Streetwise Reports report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in th
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NGEN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NGEN. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, NervGen Pharma Corp. (NGEN) ranks #369 by composite RQD confidence (45/100, grade D) and #606 by equity capitalization ($147.4M). Within this direct 5-issuer industry benchmark cohort, NGEN leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. PDSB currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NGEN at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NGEN
ACTIVE
NervGen Pharma Corp. | D | 45/100 | — | — | — | -1.46% | $147.4M | Benchmark Subject |
| DERM Journey Medical Corporation | E | 16/100 | — | 65.8% | -19.5% | -7.35% | $145.9M | /derm-vs-ngen → |
| PDSB PDS Biotechnology Corporation | D | 46/100 | — | — | -35.0% | -4.86% | $151.2M | /pdsb-vs-ngen → |
| CUE Cue Biopharma Inc. | E | 29/100 | — | — | -35.0% | -6.95% | $151.6M | /cue-vs-ngen → |
| MENS Jyong Biotech Ltd. | E | 33/100 | — | — | -28.8% | -0.53% | $142.9M | /mens-vs-ngen → |
NervGen Pharma Corp. (NGEN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $147.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.35 (-1.46% 1D, market cap $147.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, NGEN ranks #369 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DERM (Journey Medical Corporation) holds a E grade (16/100 RQD, P/E N/A, ROIC -19.5%, cap $145.9M) and PDSB (PDS Biotechnology Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $151.2M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).
For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #369 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
NGEN last traded at $1.35 (-1.46% on volume of 561,074 shares), positioning the stock -27.81% below its 50-day simple moving average ($1.87) and -51.79% below its 200-day simple moving average ($2.80). Across its 52-week range of $1.35 to $6.30, NGEN sits at the 0.0% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.18 to $1.52).
NervGen Pharma Corp. (NGEN) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.35 (-1.46% 1D, market capitalization $147.4M).
Sector: Health Care. Industry: Biotechnology: Pharmaceutical Preparations. Exchange: NASDAQ.. Is a NASDAQ-listed Health Care issuer in Biotechnology: Pharmaceutical Preparations. Products, customers, and revenue model are not described in source data.
The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations, which is not sufficient to map ripple effects.
Real-time company headlines, analyst actions, and sector developments for NervGen Pharma Corp. (NGEN) • Click "Debate This Headline" to argue it in the Roar Pit below
Stock Titan report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
Streetwise Reports report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
www.dars.gov.et report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering NervGen Pharma Corp. (NGEN) market action, institutional positioning, and fundamental catalysts.
Long NGEN at $1.37 targeting $1.73. The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest component of the rating, and the company has begun a pivotal Phase 3 trial of NVG-291.. Institutional whale score is 3/20 and the risk/reward vs. the $1.35 52-week low is skewed heavily in favor of bulls.
@ForensicBear Shorting a 3/20 institutional whale-flow stock at $1.37 is dangerous when funds are rotating into Health Care.
Sitting on the sidelines or leaning short NGEN above $1.37. The RQD rating is a D with ROIC at 0%, FCF yield at 0%, and Whale Flow scored only 5/20, while the news feed carries a RED risk-watch item on a -5.33% session drop.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $6.30.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: